Ocrelizumab

奥瑞珠单抗

Report date: 2026/05/26 20:00:28
First In Class

Base Information

Drug NameOcrelizumab
Drug Alias Nameocrelizumabum奥瑞利珠单抗OCREOCRrhuMab 2H7 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsSchizophreniaLupus Erythematosus, SystemicLupus Nephritis +[9] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2017/03/28
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[60] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech IncBiogen Idec
China Registration ClassN/A

Develop Information

Active CompaniesRoche Pharma AgRoche Pharma (Schweiz) AgF. Hoffmann-La Roche Ltd +[5] 
Inactive CompaniesUniversity of Texas Southwestern Medical CenterChugai Pharmaceutical Co LtdUniversity Of Colorado Denver
Active IndicationsSchizophreniaMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive +[4] 
Inactive IndicationsLupus Erythematosus, SystemicLupus NephritisEncephalitis +[5] 

Other Information

ATC CodeL04AG08
Related LinksWikipediaDrugBankKEGG